(no title)
justsee | 2 years ago
"We identified a statistically significant increased risk of noninfluenza respiratory virus infection among TIV recipients (Table 3), including significant increases in the risk of rhinovirus and coxsackie/echovirus infection" [1]
That's one of the complications in assessing efficacy: if the benefit in flu vaccine is potentially quite modest (as determined by some long-running studies [2]), and it causes an increased risk of other noninfluenza respiratory viruses, then we need higher-quality, more detailed studies to understand what's happening.
But based on the discussion of the Cochrane review it seems unlikely. [3]
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404712/
[2] https://www.cochrane.org/news/featured-review-three-updated-...
[3] https://community.cochrane.org/news/why-have-three-long-runn...
No comments yet.